Get the latest tech news
FDA approves new Alzheimer's treatment, donanemab from Eli Lilly
FDA approval of the new Alzheimer's treatment, which will be branded as Kisunla, follows years of setbacks.
Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the experimental Alzheimer's treatment to market, despite promising clinical trial results. We know these medicines have the greatest potential benefit when people are treated earlier in their disease, and we are working hard in partnership with others to improve detection and diagnosis," Anne White, president of Eli Lilly's neuroscience arm, said in a news release. The labels for all of the anti-amyloid treatments greenlighted by the FDA to date for Alzheimer's already carry a boxed warning about "amyloid-related imaging abnormalities" that can show up on MRI scans.
Or read this on r/technology
